Compare VYGR & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | MRBK |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 206.1M |
| IPO Year | 2015 | 2018 |
| Metric | VYGR | MRBK |
|---|---|---|
| Price | $3.81 | $17.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $16.50 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 511.1K | 112.6K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.05% |
| EPS Growth | N/A | ★ 30.34 |
| EPS | N/A | ★ 0.17 |
| Revenue | ★ $10,135,000.00 | $6,316,000.00 |
| Revenue This Year | $34.04 | $25.40 |
| Revenue Next Year | $7.92 | $8.15 |
| P/E Ratio | ★ N/A | $102.94 |
| Revenue Growth | N/A | ★ 10.13 |
| 52 Week Low | $2.65 | $11.17 |
| 52 Week High | $5.55 | $21.59 |
| Indicator | VYGR | MRBK |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 40.27 |
| Support Level | $3.71 | $16.96 |
| Resistance Level | $4.39 | $18.13 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 40.23 | 41.43 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.